Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Patricia Severns"'
Autor:
Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, Steven P. Treon
Publikováno v:
Haematologica, Vol 103, Iss 7 (2018)
Externí odkaz:
https://doaj.org/article/a2d62380073943eebab46ce7d72b1723
Autor:
Patricia Severns, Steven P. Treon, Joshua Gustine, Lian Xu, Guang Yang, Toni Dubeau, Zachary R. Hunter, Jorge J. Castillo, Kirsten Meid
Publikováno v:
Clinical Cancer Research. 24:3247-3252
Purpose: Proteasome inhibition is of proven efficacy in patients with Waldenström macroglobulinemia (WM). However, WM remains incurable with standard treatments. Novel agents, safe and effective, are needed. Patients and Methods: We designed a prosp
Autor:
Sara J. Buhrlage, Toni Dubeau, Zachary R. Hunter, Patricia Severns, Amanda Kofides, Maria Demos, Maria Luisa Guerrera, Nathanael S. Gray, Guang Yang, Christopher J. Patterson, Steven P. Treon, Kirsten Meid, Jinhua Wang, Nicholas Tsakmaklis, Jorge J. Castillo, Gloria Chan, Xia Liu, Manit Munshi, Lian Xu, Joshua Gustine, Jiaji G. Chen
Publikováno v:
Blood. 131:2047-2059
Acquired ibrutinib resistance due to BTKCys481 mutations occurs in B-cell malignancies, including those with MYD88 mutations. BTKCys481 mutations are usually subclonal, and their relevance to clinical progression remains unclear. Moreover, the signal
Autor:
Joshua Gustine, Patricia Severns, Toni Dubeau, Kirsten Meid, Zachary R. Hunter, Jorge J. Castillo, Steven P. Treon, Guang Yang, Lian Xu
Publikováno v:
British Journal of Haematology. 184:1011-1014
Autor:
Yang Guang, Lian Xu, Steven P. Treon, Jorge J. Castillo, Toni Dubeau, Kirsten Meid, Patricia Severns, Zachary R. Hunter, Joshua Gustine
Publikováno v:
American Journal of Hematology. 93:511-517
Ibrutinib is the first approved therapy for symptomatic patients with Waldenström macroglobulinemia (WM). The reasons for discontinuing ibrutinib and subsequent outcomes have not been previously evaluated in WM patients. We therefore conducted a ret
Autor:
Jiaji G, Chen, Xia, Liu, Manit, Munshi, Lian, Xu, Nicholas, Tsakmaklis, Maria G, Demos, Amanda, Kofides, Maria Luisa, Guerrera, Gloria G, Chan, Christopher J, Patterson, Kirsten, Meid, Joshua, Gustine, Toni, Dubeau, Patricia, Severns, Jorge J, Castillo, Zachary R, Hunter, Jinhua, Wang, Sara J, Buhrlage, Nathanael S, Gray, Steven P, Treon, Guang, Yang
Publikováno v:
Blood. 131(18)
Acquired ibrutinib resistance due to BTK
Autor:
Maria Demos, Maria Luisa Guerrera, Lian Xu, Christopher J. Patterson, Toni Dubeau, Guang Yang, Jiaji Chen, Manit Munshi, Zachary R. Hunter, Jorge J. Castillo, Robert Manning, Amanda Kofides, Steven P. Treon, Joshua Gustine, Kirsten Meid, Xia Liu, Patricia Severns, Nicholas Tsakmaklis, Gloria Chan
Publikováno v:
British journal of haematology. 180(3)
MYD88 mutations are present in 95% of Waldenstrom Macroglobulinaemia (WM) patients, and support diagnostic discrimination from other IgM-secreting B-cell malignancies. Diagnostic discrimination can be difficult among suspected wild-type MYD88 (MYD88W
Autor:
Jorge J. Castillo, Kirsten Meid, Patricia Severns, Joshua Gustine, Steven P. Treon, Lian Xu, Toni Dubeau, Zachary R. Hunter
Publikováno v:
Blood. 130:802-802
Background: The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is the first approved therapy for patients with symptomatic Waldenström macroglobulinemia (WM). Discontinuation of ibrutinib has been associated with an adverse prognosis in patients
Autor:
Joshua Gustine, Jorge J. Castillo, Xia Liu, Gloria Chan, Guang Yang, Toni Dubeau, Patricia Severns, Lian Xu, Steven P. Treon, Zachary R. Hunter, Amanda Kofides, Maria Demos, Jiaji Chen, Manit Munshi, Christopher J. Patterson, Nickolas Tsakmaklis
Publikováno v:
Blood. 130:4011-4011
Waldenstrom's Macroglobulinemia (WM) is characterized by bone marrow (BM) involvement of IgM secreting lymphoplasmacytic lymphoma. Whole genome sequencing identified somatic activating mutations in MYD88 and CXCR4 in 95% and 35-40% of WM patients, re